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1. Executive Summary
“One Life, One Knowledge: Technology To Integrate”
In spite of the human need to reduce to parts in order to understand, life is the 
result of an intricate systemic interaction between very many processes occurring at 
radically different spatial and temporal scales. Every day worldwide biomedical 
research and clinical practice produce a huge amount of information on such processes. 
But this information is highly fragmented, and its integration is largely left to the 
human actors, who find this more and more difficult as the breadth and depth of 
information available increases exponentially.  We need to develop a new approach, 
which makes possible the integration of information, and simplifies its transformation 
into integrated knowledge.  
The European Union and the United States of America are investing substantial 
research funding in the development of frameworks of computational methods and 
technologies that make possible an integrative approach to biomedical research and 
clinical practice.
This approach that in Europe is called “Virtual Physiological Human” (or VPH for 
short), involves laboratory and clinical data collections, information databases, models 
repositories, as well as simulation, information and communication technologies that 
make it possible to overcome the “reductionist chaos” produced by the fragmentation 
and the dispersion of scientific and clinical data, information, and knowledge that 
together compose what we humans know and understand about the biological 
mechanisms of life and disease.
These investments in VPH research are largely motivated by the need for 
improved healthcare delivery: as all health information becomes digital, the complexity 
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of care increases, and pressure imposed by growing demand and shrinking budgets. 
The way to achieve the dream of a personalized, preventive, and participative medicine 
at sustainable costs is the systematic integration of all available data, information and 
knowledge.
Some results of these research projects are finding their way to clinical deployment 
and industrial exploitation; in Europe some of the early VPH projects funded by the 
DGINFSO “ICT for Health” unit have already entered initial phases of clinical trials, 
with promising results suggesting that VPH technology can be used to address 
particular clinical problems.
The time is ripe to go to the next level: to coordinate research efforts toward the 
complete integration of all data, information, and knowledge about human physiology 
and pathology into a global “VPH cyberinfrastucture” that will produce socioeconomic 
benefits by:
! Enhancing the understanding of diseases, promoting prevention and early 
diagnosis;
! Accelerating the development pipeline and the assessment of safety and 
efficacy for innovative drugs and medical devices;
! Assisting the medical professional in coping with “information overload”;
! Fostering the development of new healthcare policies that promote a more 
integrative approach to complex diseases and to the promotion of an 
active and healthy aging.
But this will be successful only if Europe and United States elaborate a joint 
policy. This document aims to illustrate the reasons why we, the academic, industrial 
and clinical stakeholders of the VPH initiative recommend the European and United 
States governments:
! Work together on a common policy to harness outcomes of all VPH-type 
research efforts toward the creation of a global VPH Cyberinfrastructure, 
by ensuring that all repositories of data and models, as well as all the 
methods and technologies developed during these research projects 
funded by governmental agencies are mutually interoperable.
! Support the establishment and the operations of an International 
Multistakeholder Advisory Group responsible of elaborating a collective 
vision, as well as the minimum set of standards and the technical 
guidelines that ensure the interoperability and the integratibility of all 
VPH resources into the global VPH Cyberinfrastructure, to achieve the 
vision of the Virtual Physiological Human.
M. Viceconti and A.D. McCulloch / Policy Needs and Options for a Common Approach50
2. Preface
2.1. Purpose of this paper
The European Union, through the European Commission Directorate General for 
External Relations, is supporting the ARGOS eHealth Pilot Project. The overall goal of 
the ARGOS eHealth Pilot Project is to contribute to establishing a “Transatlantic 
Observatory for Meeting Global Health Policy Challenges through ICT-enabled 
Solutions” in order to develop and promote “Common Methods for Responding to 
Global eHealth Challenges in the EU and the US”. 
The EU and the US care about these global challenges because (a) citizens travel 
and migrate globally and there is a wish to foster good healthcare everywhere (b) the 
EU and US wish to refine their products to better penetrate global markets (c) 
experiences and lessons learned globally are useful in Europe and the United States. 
The Observatory promotes mutual understanding and learning among EU and US 
policy researchers and policy makers on the following general challenges with global 
dimension:
1. Improving health and well-being of citizens through accelerating eHealth 
strategy development and through supporting large scale eHealth 
infrastructure implementations;
2. Supporting R&D in eHealth to promote the benefits from the pursuit of 
consistent strategies.
A key output of ARGOS will be three Policy Briefs. They will concisely analyze 
and summarize project results on the three topics of the project on policy needs and 
options regarding
! Interoperability in eHealth and Certification of Electronic Health Record 
systems (EHRs);
! Measuring adoption, usage and benefits of eHealth solutions;
! Modelling and simulation of human physiology and diseases - Virtual 
Physiological Human (VPH) 
and provide recommendations for developing together and aligning trans-Atlantic 
eHealth policy & RTD strategies and cooperation in these three topical fields, including 
setting concrete goals, proposing adoption measures and processes to be followed.
The Virtual Physiological Human (VPH) is a framework of methods and 
technologies that, once fully established, will make possible the investigation of the 
human body as a whole. Started in Europe in 2005, it has rapidly grown to become one 
of the research priorities of the Information and Communication Technologies 
Programme of the EU Seventh Framework Programme for Research and Technological 
Development. In the US, VPH-type research is funded by all the federal agencies that 
participate in the Interagency and Analysis Group (IMAG), whose grantees are 
coordinated in the Modelling Multi Scale Modelling consortium.
On the Virtual Physiological Human, the ARGOS Proposal formulated these 
objectives: “Its potential from clinical and industrial perspectives as well as from the 
perspective of treating citizens with rare diseases will be at the focus of the ARGOS 
policy analyses and recommendations”.
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2.2. Genesis
The elaboration of this policy brief was coordinated by a small group of experts 
led by Marco Viceconti, responsible of the VPH NoE outreach program, coordinator of 
the VPHOP Integrated project. The prime advisor for the USA side was Andrew 
McCulloch, Chair of the IUPS Physiome and Systems Biology Committee and a 
member of the Multi Scale Modeling (MSM) consortium of the US Interagency
Modeling and Analysis Group (IMAG).  
To support them a small editorial team of experts from EU and US was formed, 
which drafted a first version of technical document aimed to the research community 
itself, the “ARGOS VPH Position paper”. This document was open to the public 
discussion on an Internet forum called Biomed Town, which has hosted all relevant 
community activities related to the VPH since its inception in 2005, and disseminated 
with the VPH News mailing list.  On the basis of the comments received a second 
revision was made, and presented at the VPH Strategic Consensus Meeting organized 
by the VPH Network of Excellence in Brussels that saw nearly 300 registered delegates, 
and at the Annual meeting of the Multiscale Modeling Consortium promoted by the 
USA Interagency Modeling and Analysis Group.  
The final revision that emerged from these public discussions was used as a basis 
to elaborate this policy brief, which was first drafted during the ARGOS Stakeholders 
meeting in Washington DC, and then opened to public discussion through Biomed 
Town.  Overall, the policy brief was exposed to over 10,000 individuals involved with 
the VPH initiative worldwide; we estimate that more than 700 experts and stakeholders 
participated to the elaboration of the position paper of our policy brief.
2.3. Key Policy Messages 
We recommend that the European Union, its member states, and the United States 
governments:
! Agree on a common policy to harness the outcomes of all VPH-type 
research efforts toward the creation of a global VPH 
Cyberinfrastructure, by ensuring that all repositories of data and models, 
as well as all the methods and technologies developed during these 
research projects funded by governmental agencies are mutually 
interoperable;
! Support the establishment and the operations of an International 
Multi-stakeholder Advisory Group responsible of elaborating a 
collective vision as well as the minimum set of standards and the 
technical guidelines that ensure the interoperability and the integrability
of all VPH resources into the global VPH Cyberinfrastructure, according 
to the vision of the Virtual Physiological Human.
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3. Terminology
3.1. Choice of the core terms
The focus of this document is upon a global resource that will play an 
infrastructural role. However, this resource is not a distinct physical entity, but an 
organised cloud of databases, services, collections, portals, simulation engines, etc. 
accessible via the Internet.
Currently we are referring to this as the term VPH Infostructure in Europe, and 
Multi-Scale Modeling Cyberinfrastructure in the USA. 
The term Virtual Physiological Human (VPH) was first proposed by a group of 
European researchers in a white paper published in 2005, and substantiated by the 
European STEP action, which published in 2007 a full research roadmap for its 
realisation. In this roadmap the VPH is defined as a “framework of methods and 
technologies that once established will make possible to investigate the human body as 
whole”.  The VPH intends to be the technological materialisation of notions and 
objectives that had commonly been described as the Physiome, a term coined and 
adopted jointly by Jim Bassingthwaighte at the University of Washington and Denis 
Noble at the University of Oxford. The International Union of Physiological Sciences 
organized and promoted the international Physiome Project, under the leadership of 
Peter Hunter at the University of Auckland. Although the term VPH is used primarily 
in Europe, it has a very strong ethos, a clear definition, and a large number of 
documents and papers that materialise it. In the US, Systems Biology captured many of 
the key concepts of model-based integration but without a specific emphasis on the 
integrative physiological function of the whole human. Thus IMAG settled on Multi-
Scale Modeling (IMAG) to describe the ideal of Physiome research.
In computer science, the term cyberinfrastructure popularized by the NSF is now 
mature a clearly defined, for example in the Wikipedia entry: “The term 
cyberinfrastructure describes the new research environments that support advanced 
data acquisition, data storage, data management, data integration, data mining, data 
visualization and other computing and information processing services over the 
Internet. In scientific usage, cyberinfrastructure is a technological solution to the 
problem of efficiently connecting data, computers, and people with the goal of enabling 
derivation of novel scientific theories and knowledge”.  NSF has an Office of Cyber 
Infrastructure (OCI), and there is a 2007 NSF roadmap entitled “Cyberinfrastructure 
Vision for 21st Century Discovery”, which describes a general vision for all sciences, 
that fit closely to the idea we have in Europe of the VPH Infostructure.  The term 
returns 283,000 entries in Google (on 22-11-2010).
In contrast, the term Infostructure has a much less clear pedigree. Apparently, it 
first appeared in 1994, in an informal document in which the following definition is 
provided: “An infostructure is the layout of information in a manner such that it can be 
navigated -- it's what's created any time an amount of information is organized in a 
useful fashion. A table of contents is an infostructure, as is a bibliography, or an index. 
GopherSpace is an infostructure. The World Wide Web is an infostructure”. The term 
returns 105,000 entries in Google (on 22-11-2010) but most of them are not relevant 
here. For example the same is used for some companies in the area of Information 
Technology (IT) services, telecommunications, etc. The term has been adopted by the 
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Canadian healthcare services to indicate the new healthcare IT structure: “Health 
infostructure is the development and adaptation of modern systems of information and 
communications technologies in the health sector in order to improve access, efficiency, 
effectiveness and the quality of clinical or health services processes”.
After some discussion, it was agreed to use in this document the term “VPH 
Cyberinfrastructure” combination of the term VPH mostly used in Europe and that 
Cyberinfrastructure mostly used in USA. 
Another similar dichotomy between European and American terminology is that 
used to define the general application of information technology to the healthcare. This 
in USA is mostly indicated with the term Health Information Technology (HIT), 
whereas in Europe the term eHealth (electronic health) is more used.  Both will be used 
interchangeably throughout the text.
3.2. List of acronyms used in the document
FP6 EU Sixth Framework Program for Research and Technological Development 
FP7 EU Seventh Framework Program for Research and Technological 
Development
ICT Information and Communication Technology
IMAG USA and Canadian Interagency Modeling and Analysis Group
IT Information Technology
MSM Multi-Scale Modeling
NIH National Institutes of Health -– USA federal agency
NSF National Science Foundation – USA federal agency
VPH Virtual Physiological Human
4. Analysis framework
! The strategic importance of VPH research both in terms of basic 
knowledge and of socioeconomic impact was analyzed in depth in the 
VPH Research Roadmap by over 600 experts in 2006 under the 
coordination of the STEP consortium.
! Such importance was reflected in Europe in the Seventh Framework 
Program, the most important community research action, which indicated 
the VPH as one of its priorities in the Information and Communication 
Technologies Programme [1].
! In the United States, Botstein and Smarr’s BISTI (Biomedical 
Information Science and Technology Initiative) report (1999) to the NIH 
director made key recommendations emphasizing the importance of 
information technology in post-genomic medicine and health research and 
led to the creation of the National Centers for Biomedical Computing. 
This was followed by other influential reports, notably the National 
Academy of Sciences report in 2005 by Wooley and Lin on “Catalyzing 
Inquiry at the Interface of Computing and Biology”.
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! The specific need for the development of ad hoc Information and 
Communication Technologies (ICT) infrastructural components emerged 
in the 2009 update to the VPH Roadmap [2].
! This recommendation was again reflected in the seventh framework 
program, which funded in the most recent VPH call for proposals two 
large integrated projects aimed to develop essential elements of such 
infrastructures, VPH-Share, and P-Medicine.
! At the NIH, the BISTI consortium of representatives from each of the 
NIH institutes and centers was established in May 2000 to serve as the 
focus of biomedical computing issues at the NIH. Major related NIH 
initiatives include the Cancer Biomedical Informatics Grid (CaBIG), the 
Genome Informatics and Computational Biology Program and the 
Neuroscience Information Framework (NIF).
! Beyond the NIH there are also important inter-agency initiatives, 
principal among them the Interagency Modeling and Analysis Group’s 
(IMAG) Multi-Scale Modeling (MSM) initiative established in 2004, 
which brought together over 80 investigators funded by ten federal 
agencies. This call was followed by the NIH call in 2008 for research 
proposals on “Predictive Multi-Scale Models of the Physiome”. In 2011, 
the IMAG MSM request for proposals was reinstated through 2014. 
! With respect to the integration of these new ICT research infrastructures 
with those resources already available and largely in use, such as the 
bioinformatics resources managed by the European bioinformatics 
Institute and the US National Center for Biotechnology Information, the 
Biomodels and CellML models repositories, the PhysiomeSpace data 
sharing service, PhysioNet, NIF and the Neuroimaging Informatics 
Technology Initiative (NIfTI), the need to integrate all these resources 
into a coherent framework is becoming evident.
! Similarly, it is now recognised that locked up in our hospitals is a wealth 
of data and information that in principle could be integrated with data
collections produced by research activities and clinical trials, in order to 
maximise their usage and potential benefits.
! All these roadmaps, position papers, research funding allocations, in-
depth analyses point in the same direction: in spite of the great difficulties 
involved, all biomedical data, information, and knowledge should be 
captured digitally, and should be integrated into a coherent framework 
worldwide.  
! A Memorandum of Understanding was recently signed between the 
European Commission and the United States Department of Health and 
Human Services on Cooperation Surrounding Health Related Information 
and Communication Technologies, where are laid down the foundations 
for a global conceptual framework that articulates how health-related 
information and communication technologies support improved health [3].
In this policy brief we analyse how research activity can be aligned and deployed 
so as to establish a global VPH cyberinfrastructure that can make significant impact 
first onto biomedical research and then onto the clinical practice and the biomedical 
industry, as long as it is properly developed, operated, serviced, and maintained.
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The analysis framework was organised around six aspects:
! Needs and challenges that could be addressed by the Virtual Physiological 
Human;
! Policy and strategic approaches being used to tackle these challenges; 
! Results these strategies have produced so far, and their limitations;
! Methodological challenges to be faced;
! Lessons learned so far, and need for future actions;
! Recommendation for the development of a trans-Atlantic joint policy.
5. What are the issues? 
5.1. Let’s go digital
By 2020 we can expect the digitalization of virtually all healthcare information, at 
least in the developed world. Despite the costs involved, the lack of a digital 
information workflow within a healthcare organization will eventually incur a higher 
cost in the effectiveness of healthcare delivery, which could threaten to create a digital 
divide between fully digital healthcare providers that will benefit from this integration 
trend, and those that are not.
This issue will be amplified by increasing demand from patients for secure online 
access to personal health records. By 2020, the elderly population will comprise 
citizens who retired in the ‘90s or later, the vast majority of whom will expect to have 
the same degree of digital access to all their health information as they do for all their 
other personal information.
Investments in healthcare Information Technology (IT) in the next few years must 
account for the trend toward integration of all available data, and they should 
emphasize solutions that facilitate integration; the idea that the information systems of 
our hospitals are islands, isolated from the rest of the digital world, is rapidly becoming 
obsolescent. 
5.2. Let’s get personal
Modern medical science is all about the “average person”. The signs of a disease, 
the efficacy of a drug, or the appropriateness of a therapy, are always observed on 
many patients, and from them an “average response” is derived, which is then 
considered valid for any other patient. 
But as our therapies become more and more complex, the best option for an 
individual patient is frequently a balance between opposing factors; the option 
considered the best based on the “average responses” might not be actually the best for 
each individual.  
The solution is personalization of therapy. Some experts suggest that 
personalization is only related to the genes. The way our genes are, as we received 
them from our parents, surely have an influence of how we shall react to a medicine.  
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But we are lot more than our genes.  If we have been smoking all our life, if we drink a 
lot, if we run 20 miles per day, this can make a lot of difference.  So personalization 
involves the integration of all details on the patient, not only the genetic ones.
5.3. Explanation-based medicine
A term that is quite popular nowadays is “evidence-based medicine”.  This means 
that every doctor should base his/her medical decisions on solid evidences that such 
decision is the correct one.  By observing a reporting the health condition of million of 
individuals over the centuries we now know that there are some solid evidences.  For 
example, if you get a cold, an aspirin can relieve you of some symptoms.  It might not 
be true for all or under all conditions, but it has found true for millions of peoples in 
millions of conditions: this is evidence. So when a doctor prescribes a drug to a patient, 
we expect he/she takes this decision not because he personally thinks is a good idea, 
but because there is evidence based on clinical trials to support the decision.
However, the fact that we know for sure that aspirin takes away cold symptoms 
does not necessarily means that we know why this happens. Do we care? Well, in 
many cases probably not. But in some cases, having an explanation of why something 
happens is critical. For example a certain drug worked well for a lot of people with a 
certain disease; this is evidence. But it does not work for me, even if I am supposed to 
have the same disease. Population-based evidence cannot help in solving this problem.  
But if we can provide an explanation of how the drug works, we can search for a 
specific condition that I have but that others tested did not have, for example another 
disease, a certain genetic predisposition. So evidence-based medicine is important, but 
to go further we need to add explanation-based medicine.
But how can we produce such explanations? When available they come from 
scientific studies. But in many other cases what we observe is the result of very many 
complicated processes happening all together.  In many other domains of science, when 
we must deal with problems that are too complicated for our brains, we resort to 
mathematical models. Take weather forecasting: to predict tomorrow’s weather, we 
need to take into account so many factors, and so many calculations, that it could take 
months, if not years to come up with an answer, which of course by that time would be 
useless. But if we write all we know about weather in a mathematical model, a 
computer can do those calculations fast enough predict the weather for tomorrow in a 
few hours.  
Can we use the same approach to provide explanations in medicine? Yes, now we 
can. The problem is that even the simplest medical problem is much more complicated 
than what any traditional computer model can deal with.  But recently we started to 
develop a whole new generation of biomedical simulation models that can predict 
accurately what happen in the human bodies under many different conditions, and 
many more are developed every day.  In a near future we can imagine personalized 
computer models that provide the most plausible explanation for each patient, making 
the dream of explanation-based medicine closer to reality. 
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5.4. Integration will rule them all
Another problem that we have is fragmentation.  Take for example health data. 
Most of the information that describes our health over the years is probably stored in 
digital format, but it is spread over several hospitals, clinics, points of care, family 
doctors, pharmacies, etc.  No one can really see my health history as a whole, including 
myself. We need to make biomedical information accessible by anyone from 
everywhere and through whatever type of computer, mobile devices, etc. And we need 
to do this without compromising the security, confidentiality, and integrity of personal 
health information, among the most sensitive information computer systems can store.
A second dimension of the problem of fragmentation is that of the integration of 
knowledge. We know so much about the human body nowadays, that no one can know 
it all.  So every medical professional, every biomedical researcher becomes a specialist 
of something, and they try to know as much as possible about a very specific topic.  
This has been happening for some time, but now we start to realize that in the long run 
this is not such a good idea. Indeed, while we can attempt to separate knowledge about 
the human body into parts, the reality is that the human body is one, and works as a 
whole. 
A third dimension, less obvious for non-experts, is the fragmentation, or better 
separation, between biological research and medical practice. In spite of all claims, 
going “from the bench to the bed” remains largely an unresolved issue. The problem 
again is fragmentation, but this time in the production of knowledge: reducing what we 
are studying to its smallest part make it easier to understand, but frequently prevent us 
to understand that such small part is indeed a part, the part of a bigger and more 
complex system. 
5.5. Faster, cheaper, safer innovation in healthcare
The relationship between biomedical research and clinical medicine has also 
another dimension: that of the development of new methodologies, technologies, and 
pharmacological products.  The more we advance the more this process become 
difficult, expensive, and slow. Again, the fragmentation of knowledge and of its 
production processes is the main culprit. 
5.6. And the patient? In the centre!
A key concept that is recurring in debates on the future of healthcare delivery is the 
need to keep the patient at the centre of the information cloud. In reality, the human 
relationship between the patient and the doctor remains the core of medicine, which 
will never be reducible or simplifiable. In relation to age, culture, social status, and 
geographical location, some patients will always expect to transfer the major part of 
their health responsibility to their doctor, whereas others will fight to retain total 
control, even when this is ill advised. This issue ultimately must balance the needs of 
the individual with those of society and of the other stakeholders, which often becomes 
a complex philosophical and political issue. 
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6. Policies, strategies, approaches presently pursued
6.1. European Commission: the Virtual Physiological Human
In Europe the need for integration in biomedical research and clinical practice was 
approached with a pragmatic perspective.  Having recognized the need for such 
integration, the European Commission started to support the development of the 
Virtual Physiological Human (VPH), intended as a framework of methods and 
technologies that once established will make possible the investigation of the human 
body and of its diseases in an integrated way.  So the accent was placed on the 
development of the tools, primarily information technology tools that can make 
possible such integration.
The VPH started in Europe primarily as a research initiative; however, the fact that 
it was initially funded by the ICT for Health unit imposed from the beginning a 
stronger translational and industrial perspective. Toward the end of the Sixth 
Framework Programme (FP6) a support action called STEP steered the development of 
a research roadmap for VPH research. Even if STEP was a European action the 
scientific advisory board that was formed to supervise the consensus process that led to 
the roadmap included experts from Japan, New Zealand, and of course the USA. 
STEP was a great success mostly thanks to the enthusiastic participation of over 
600 experts in the elaboration of the roadmap. This happened primarily because the 
times were ripe: in many areas of biomedical research spontaneous exploration were 
started on the use of predictive computer models in an integrative way so as to properly 
represent processes happening at radically different space-time scales. This approach 
was already quite advanced in cardiac modeling, but some researchers were starting to 
apply it to other biomedical problems.
The VPH research roadmap, which thanks to the annual updates is still the primary 
reference document for the European VPH initiative, identified as the primary 
challenge in integrative research the development of an exhaustive framework of 
methods and technologies that once fully established would have made possible the 
investigation of the human body as a whole. 
Today we recognize the VPH is not only methods and technologies, but also a 
global cyberinfrastructure that unifies all data, information, and knowledge on the 
human body we are accumulating worldwide.
As part of the Seventh Framework Program (FP7) the EC selected in a first 
funding round a network of excellence, two large integrated projects, and 12 medium-
sized projects. A second funding round closed recently, and a number of new projects 
will soon kick-off; meanwhile a third funding round is already planned for early 2012
Meanwhile also national agencies of European member states started to invest 
resources in VPH research.  Two examples are the Epitheliome project funded by UK 
EPSRC, or the €40m virtual liver project funded in Germany.
.
This first batch of grants was followed the year after by five internationalization 
projects, aimed to reconnect these research experiences.
6.2. US National Institute of Health Grants on Physiome Models
In USA the development of the integrative research vision was a bit different, with 
more focus on basic science research (especially at the molecular and cellular scales) 
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and developing computer science infrastructure for biomedical research, producing a 
stronger academic development. One outgrowth of the MSM initiative that specifically 
encouraged the extension of multi-scale modeling to “higher scales” of biological 
organization and applications to clinical translation was the NIH program first 
announced in 2008 on “Predictive Multiscale Models of the Physiome in Health and 
Disease”. This program announcement continues to be reissued and currently ten NIH 
institutes and centers including the National Institute of Biomedical Imaging and 
Bioengineering, the National Cancer Institute, the National Heart, Lung, and Blood 
Institute, the National Institute on Aging, the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases, the National Institute on Deafness and Other 
Communication Disorders, the National Institute on Drug Abuse, the National Institute 
of Environmental Health Sciences, the National Institute of General Medical Sciences, 
the National Institute of Neurological Disorders and Stroke and the National Library of
Medicine. The goal of this solicitation is to move the field of biomedical computational 
modeling forward through the development of more realistic and predictive models of 
health and disease. NIH recognizes the need for sophisticated, predictive, 
computational models of development and disease that encompass multiple biological 
scales. In 2011, the IMAG MSM call for proposals was renewed through 2014.
6.3. NSF Cyberinfrastructure policy
The National Science Foundation in the US has long been the focal point for 
research on cyberinfrastructure. Its 2007 report “Cyberinfrastructure Vision for 21
st
Century Discovery” [4] summarizes the NSF vision for the use of computing systems, 
data, information resources, networking, digitally enabled-sensors and instruments, 
virtual organizations and observatories, interoperable software services and tools, 
together with interdisciplinary teams of professionals in enabling new advances in 
scientific research and education. At the NIH, the National Center for Research 
Resources has supported research resources and centers over the past 15-20 years that 
aim make the NSF sponsored progress in IT research and cyberinfrastructure 
development accessible and useful to the biomedical research community. Wooley’s 
2004 report at NSF entitled Building a Cyberinfrastructure for the Biological Sciences 
[5] outlines the needs to the biological science community in this regard.
6.4. Memorandum of Understanding 
The 2010 “Memorandum of Understanding Between The United States 
Department of Health and Human Services and the European Commission on 
Cooperation Surrounding Health Related Information and Communication 
Technologies” is a remarkable signal and encouragement to all stakeholders that 
common standards and interoperability in eHealth will bring opportunities for a global 
approach for the benefit of patients, health systems and the market. The memorandum 
encourages more effective use of health related information and communication 
technologies in healthcare delivery including disease prevention and health promotion 
services. Of relevance to the VPH initiative is the encouragement to develop a global 
conceptual framework “that articulates how health-related information and 
communication technologies support improved health” and also “the promotion of 
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continuous innovation”. An approach on a global scale with the focus on boosting 
innovation through international cooperation lies at the heart of VPH 
cyberinfrastructure. 
6.5. VPH infrastructure projects: VPH-Share and P-Medicine
Also the European Commission recognized the need for a global 
cyberinfrastructure that unifies all data, information, and knowledge on the human 
body, by funding two large-scale research projects aimed to develop core information 
technologies for the creation of such infrastructure.
VPH-Share will develop the organisational fabric (the infostructure) and integrate 
the optimised services to (1) expose and share data and knowledge, (2) jointly develop 
multiscale models for the composition of new VPH workflows, (3) facilitate 
collaborations within the VPH community. Four flagship workflows (from @neurIST, 
euHeart, VPHOP, Virolab) provide existing data, tools and models, engage with the 
services developed by VPH-Share to drive the development of the infostructure, and 
pilot its applications. Data sources are usually clinical data from individual patients -
medical images and/or biomedical signals - sometimes with population information. 
The operations range from secure access and storage through annotation, data inference 
and assimilation, to complex image processing and physics-based mathematical 
modelling, to data reduction and representation. The project focuses on a key 
bottleneck – the interface with the wealth of data from medical research infrastructures 
and from clinical processes. VPH-Share will provide the essential services, as well as 
the computational infrastructure, for the sharing of clinical and research data and tools, 
facilitating the construction and operation of new VPH workflows, and collaborations 
between the members of the VPH community. Evaluating the effectiveness and fitness-
for-purpose of the infostructure and developing a thorough exploitation strategy are key 
activities, creating confidence in the communities. The consortium, through its optimal 
mix of medical, mathematical, engineering, software & hardware and industrial 
knowledge and expertise from the EU and internationally, will make this effort a 
success, delivering to European citizens clinically useful outcomes that will benefit 
society. The duration of the project is 4 years, its budget is € 15.5m, and the requested 
EC contribution is € 11.3m.
P-medicine aims to create an infrastructure that will facilitate the development 
from current medical practices to personalized medicine. The main drivers will be 
clinicians. The project is scenario based. Two categories of scenarios will be addressed:
! The composition of large, pseudo-anonymized datasets from multiple 
sources, used for the development of VPH tools;
! The use of data obtained from a single patient to run a simulation 
workflow in support of an individual clinical decision making process;
The infrastructure of p-medicine will consist of an IT and a clinical research 
infrastructure that are smoothly interconnected and guarded by a legal and ethical 
framework. Previous R&D work done in European funded projects like ACGT 
(Advancing clinicogenomic trials in cancer), ContraCancrum and ECRIN (European 
Clinical Research Infrastructures Network) fits perfectly into this approach and will be
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interlinked. The system architecture will be modular, such that switching to the p-
medicine system is not an all-or-nothing decision. 
In p-medicine anonymized data and tools will be stored in repositories potentially 
as private cloud services and will be open source. The data warehouse serves as a data 
collection for running VPH simulations and testing developed tools, for which 
standardization and semantic interoperability is a major issue to be solved. Most of the 
data come from clinical trials. Data from clinical information systems will be made 
available by a 'push' model, where data owners initiate data transfers. Access to 
biobanks will help to answer research questions without running new trials. Allowing 
patients to decide at any time what kind of research can be done with their data and 
their biomaterial supports patient empowerment. This will be specifically addressed by 
the legal and ethical work package. P-medicine will develop eLearning tools to train 
and educate end-users.  Three areas of clinical trials will focus on three different 
aspects of the developed framework:
! The Wilms tumour trial will be used to employ the newly developed and 
validated tools of p-medicine. The trial also provides data for the 
Oncosimulator testing a specific Wilms Tumour scenario (continuation of 
ACGT)
! The breast cancer trials will be used for the validation of decision making 
tools and data acquisition, sharing, joining and analyzing and the breast 
cancer neoadjuvant pharmacodynamic phase II trial will be used to extend 
the VPH tools.
! The leukaemia trial and the breast cancer neoadjuvant pharmacodynamic 
phase II trial will be used to run system biology and postgenomic 
dynamic scenarios to find, also by using simulations based on systems 
biomedicine modelling approach, individual risk factors for decision 
making and to validate the proposed models 
To sustain a self-supporting infrastructure realistic use cases will be build that can 
be run easily and show tangible results for end-users in their daily practice.
6.6. EU policy on biomedical e-infrastructures 
The European Commission is establishing a number of European ICT research 
infrastructures (e-infrastructures) targeting biomedical research. Among the others:
! Generic infrastructure for connectivity in Europe with links world-wide: 
GEANT (http://www.geant2.net/)
! Generic infrastructure for distributed computing in Europe with site 
world-wide: EGI (http://www.egi.eu/)
! Generic infrastructure for supercomputing in Europe: PRACE 
(http://www.prace-project.eu/)
! Biobanking and Biomolecular Resources Research Infrastructure 
(BBMRI) 
! European Life Sciences Infrastructure for biological information 
(ELIXIR)
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! European Clinical Research Infrastructures Network (ECRIN) 
! European Research Infrastructure for Imaging Technologies in Biological 
and Biomedical Sciences (Euro-BioImaging)
! European Advanced Translational Research InfraStructure in Medicine 
(EATRIS)
! Biological NMR infrastructure (Bio-NMR)
! The European Mouse Mutant Archive (EMMA)
! European Infrastructure for phenotyping and archiving of model 
mammalian genomes (INFRAFRONTIER)
! Integrated Structural Biology Infrastructure (INSTRUCT)
There are also complementary e-infrastructures that are aimed at managing very 
large databases, networking services, and high-performance computing systems. As an 
example we provide here some details on one of them, the ELIXIR bioinformatics 
infrastructure.
ELIXIR (www.elixir-europe.org) is a European Infrastructure that unites Europe's 
leading research organisations in managing the staggering volume of biological data 
being generated every day in publicly funded research. This large-scale initiative will 
provide the facilities necessary for life science researchers to share, analyse and protect 
our rapidly growing store of information about living systems.
In recent years, many European countries have been investing heavily in biological 
research. As a result, life scientists are finding out more every day about genes, 
proteins and the complex networks at play in living things. The results of these 
experiments are a goldmine for life scientists, both in academia and industry. This 
information provides valuable insights into how we and other life forms (like plants 
and bacteria) grow and change, and how diseases progress. It helps us to understand a 
patient's family history better, and to discover molecules that can be used to make new 
drugs to treat disease. It can also inform the way we plant crops, or how we might use 
them differently.
Advances in DNA sequencing and in other areas have led to massive growth in the 
amount of new knowledge being generated in biological experiments - in fact, the 
volume of new data is doubling every five months or so. This growth in data generation 
far surpasses the growth in storage capacity. Yet all of this information must be stored, 
managed and quality controlled by experts in biology, chemistry and bioinformatics. In 
addition, new types of data - for example, images acquired using microscopes, 
physiological datasets, mathematical models - will need to be integrated with the old. 
This requires innovative tools as well as vast computational and storage resources. The 
collection, curation, storage, archiving and integration of these data present an immense 
challenge that cannot be handled by a single organisation or country alone. It requires 
international coordination. ELIXIR brings together Europe's leading bioscience 
facilities to manage biological data in a sustainable way. This pan-European initiative 
aims to enable all facets of the life science community - from health to agriculture - to 
extract optimum value from work that has already been done, and whose nature we can 
now only imagine.
ELIXIR is entering its construction phase, and many leading researchers and 
institutions throughout Europe are working together to ensure that it is robust, forward-
looking and sustainable. Coordinated by the European Molecular Biology Laboratory's 
European Bioinformatics Institute (EMBL-EBI), ELIXIR already has significant 
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financial backing from Denmark, Finland, Spain, Sweden and the United Kingdom. In 
total, 53 European institutes in 23 countries have put forward proposals to participate.
6.7. Europe 2020 Innovation Union
The Council of the European Union recently concluded on the European 
Commission communication [6] "Europe 2020 Flagship Initiative: ‘Innovation 
Union’: Accelerating the transformation of Europe through innovation in a fast 
changing world" [7] as well as the flagship initiative "Digital Agenda", in the context 
of the Europe 2020 strategy.  In this document the European Commission seizes 34 
commitments with respect to innovation from now to 2020. Two of them are of 
particular relevance here:
! Innovation Union commitment #31. The European Union and its Member 
States should treat scientific cooperation with third countries as an issue 
of common concern and develop common approaches. This should 
contribute to global approaches and solutions to societal challenges and to 
the establishment of a level-playing field (removing barriers to market 
access, facilitating standardisation, IPR protection, access to procurement 
etc.). In 2012 together with the ERA Framework, the Commission will 
propose common EU / Member States priorities in S&T as a basis for 
coordinated positions or joint initiatives vis-à-vis third countries, building 
on the work of the Strategic Forum for International Cooperation. In the 
meantime, the EU and Member States should act in a concerted manner 
when engaging in S&T agreements and activities with third countries. 
The potential scope for "umbrella" agreements between the EU and 
Member States with third countries will be explored.
! Innovation Union commitment #32. The European Union should step 
up its cooperation on the rollout of the global research 
infrastructures. By 2012, agreement should be reached with 
international partners on the development of research infrastructures, 
including ICT infrastructures, which owing to cost, complexity 
and/or interoperability.
In the same document, the Council endorses also the ongoing work by the 
European Commission in bringing forward the pilot European Innovation 
Partnership (EIP) on Active and Healthy Ageing, the overarching goal of which is 
to increase on average, by 2020, the healthy lives of Europeans by two years. The pilot 
European Innovation Partnership on Active and Healthy Ageing will pursue three 
goals: 
! enabling EU citizens to lead healthy, active and independent lives while 
ageing;
! improving the sustainability and efficiency of social and health care 
systems;
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! and improving the competitiveness of the markets for innovative products 
and services, responding to the ageing challenge at both EU and global 
level, thus creating new opportunities for businesses.
The approach to integrate all available data, information and knowledge in order to 
form a personalized, preventive, and participative medicine at sustainable costs, and to 
foster the development of new and healthcare policies through break-through 
innovative business and technology models, makes the VPH initiative in itself a 
flagship candidate community for innovations in active and healthy ageing. VPH 
endorses the proposal that “the pilot partnership provides [...] actors with a forum in 
which they can, united around the common goal, identify and overcome potential 
innovations barriers”.
7. Past and present achievements
7.1. VPH: early results
The VPH is a broad initiative, which targets virtually all aspects of biomedical 
research and clinical practice.  Currently, we estimate that over 100 research projects 
developing and applying VPH-related technology are active worldwide, with clinical 
targets that go from the early diagnosis of the Alzheimer’s disease to the prevention of 
osteoporotic fractures in the elders. To provide an exhaustive coverage of the early 
results produced by all these research activities is clearly impossible.  Here we mention 
a few examples, which can provide the impression of what VPH research can achieve.  
For a more detailed overview, the reader can refer to the recent article on 
Physiome/VPH research on Biomedical Computation Review [8].
! The Living Human Digital Library Project has created the first multiscale 
data collection on the skeletal system in the world, and made it available 
to the research community through the Physiome Space data sharing 
service [9].
! The AneurIST project developed an integrative approach that for the first 
time was able to consider all factors that concur to the rupture of a 
cerebral aneurysm [10].
! Sim-e-Child’s project developed a combination of medical imaging and 
personalized modelling that makes possible to visualise the blood flow 
inside the heart over the entire cardiac cycle [11].
! The VPHOP model was able to accurately predict the incidence in the 
Italian general population of osteoporotic fractures [12].
! A combination of imaging and computer models was also used by the 
PredictAD researchers to identify and quantify changes in brain that could 
be used to make early and more accurate diagnosis of the Alzheimer’s 
disease [13].
! Biologically detailed models of the heart function now promise to provide 
insights into rare life-threatening disorders. For example, a recent model 
made predictions of the clinical effects of a rare gene mutation [14]. Some 
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of the alterations in the electrocardiogram predicted by this computational 
model of life-threatening genetic Long-QT Syndrome were actually first 
reported in human subject [15] the year after the model was published. 
This is one of the first examples of a computer model predicting the 
clinical effect of a rare genetic disease before it had been recognized 
clinically.
7.2. Existing VPH-related cyberinfrastructure
Being the VPH a relatively young initiative, only small number of dedicated 
cyberinfrastructures existing to date, mostly devoted to the sharing of data, models, or 
tools.
! Created as an output of the LHDL project, the PhysiomeSpace digital 
library service provides a free-for-no-profit service for the sharing of 
large volumes of biomedical research data of all kinds [16].  Currently 
running as a beta service, it already hosts over dozen of precious data 
collections for researchers and clinical experts [17].
! The PhysioNet repository makes freely available a large collection of data 
on physiological signals, such as electrocardiograms, for research 
purposes [18].
! The CellML repository hosts nearly 500 models of physiological and 
pathological processes at the cellular or metabolic level, that researchers 
worldwide can freely download and reuse in their studies [19].
! The Biomodels databases hosts over 600 models of biochemical reactions 
and other processes relevant for biological research [20].
! The VPH Toolkit hosts a directory of all software tools available for VPH 
research [21].
! SimTk.org hosts modelling tools and models developed by Simbios, the 
United States National NIH Center for Biomedical Computing focusing 
on Physics-based Simulation of Biological Structures [22].
! The National Biomedical Computation Resource [23] develops multi-
scale modelling tools and cyberinfrastructure for the biomedical research 
community with applications to drug development, infectious disease, 
neuroscience and cardiovascular diseases.
! The e-Infrastructure neuGRID is a virtual imaging laboratory where 
neuroscientists can carry out computationally intensive experiments on 
large image datasets of functional and structural scans of brains of 
patients with Alzheimer’s and other neurodegenerative diseases [24]. The 
international cooperation chapter (outGRID) aims to kick-start 
interoperability of neuGRID with related infrastructures in North America 
(LONI in the US and CBRAIN in Canada) [25].
M. Viceconti and A.D. McCulloch / Policy Needs and Options for a Common Approach66
7.3. Early success stories in US-EU cooperation on VPH research 
Musculoskeletal diseases
The musculoskeletal apparatus is perhaps the organ system where the need for the 
integrative approach advocated by the Virtual Physiological Human (VPH) initiative is 
most pronounced. Neuromotor control involves the entire body, whereas the processes 
involved in muscle excitation, bone and muscle adaptation, musculoskeletal ageing, 
and most musculoskeletal diseases take place at the molecular level. What we observe 
clinically is the emergence of complex bidirectional interactions between these two 
extreme dimensional scales, and of everything (cells, tissues, organs) in between them.
The traditional reductionist approach is reaching dead ends in several important areas 
of musculoskeletal research, such as those related to osteoporotic fractures, the 
pathophysiology of growth in cerebral palsy children, the pathogenesis of rheumatoid 
arthritis and osteoarthritis, etc. It is becoming evident that the path forward is the 
development of new Information and Communication Technology (ICT) that makes 
personalised, predictive, and integrative (PPI) musculoskeletal medicine possible.
Worldwide, the two largest research projects that are developing technology for 
PPI musculoskeletal medicine are the Osteoporotic Virtual Physiological Human 
(VPHOP) integrated project funded by the European Commission, and the Center for 
Physics-based Simulation of Biological Structures (SIMBIOS), one of the National 
Centers for Biomedical Computing (NCBCs) funded by the United States National 
Institutes of Health. These two projects are targeting the same strategic objective and 
developing highly complementary technologies. This unique condition creates an 
compelling opportunity for international collaboration, one which would dramatically 
increase the international impact of the work being done by the VPHOP project, and 
foster global cooperation on one of the grand challenges of biomedical research.
With the Neuro Musculo Skeletal Physiome (NMS-Physiome) project, funded by 
the European Commission as part of the internationalization initiative for VPH Projects, 
the SIMBIOS and VPHOP consortia intended to establish a more organic and 
synergistic cooperation.  Already in the first year of activity, this collaboration 
produced already some important results:
! Integrate the projects’ research communities: each consortium has its own on-
line portal, to provide the research community they serve with dissemination, 
community building, and data management services. SIMBIOS’s is called 
SimTk.org, VPHOP’s is called BiomedTown.org.  Thanks to NMS-Physiome 
the two communities are now interconnected, through mutual membership, 
cross-dissemination, global search services, etc.  Together these two on-line 
services are supporting the work of over 8000 researchers worldwide.
! Integrate the projects’ tools: SIMBIOS’s OpenSIM is probably the best 
software for musculoskeletal modeling; VPHOP’s NMS-Builder software is 
capable to elaborate the patients’ data into such models.  The two tools, both 
free available for research purposes, are now being fully integrated, so as to 
provide to laboratory and clinical researchers worldwide a complete workflow 
for the creation of personalized models of the patient’s musculoskeletal 
system.
! Integrate the projects’ knowledge: researchers at Stanford University in 
California and at the Rizzoli Institute in Italy are working together on a new 
modeling approach that could dramatically improve the way we cope with 
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patients affected by a number of musculoskeletal diseases and also with 
various degree of neuromotor disability, which is typical scenario for elder 
patients. 
Cancer-related diseases
Predictive and personalized cancer treatment seems to be the next big opportunity 
in the fight against cancer, especially since traditional clinical frameworks seems to be 
reaching their limits. The EU Virtual Physiological Human (VPH) initiative has 
invested on improving cancer treatment by administering therapy that most closely 
matches the precise individual circumstances of each individual patient taking also into 
consideration prediction models. The Interagency Modeling and Analysis Group 
(IMAG) held an IMAG Futures Meeting [26] on December 15-16, 2009 on the 
National Institutes of Health (NIH) Campus, discussing the impact of computational 
modeling. Success cancer multiscale modeling stories includes the BRCAPro and 
CISNET (cisnet.cancer.gov) models that have made an impact in breast cancer 
management. Initial evidence both in the EU
2
To achieve this sooner rather than later EU-US collaboration is mandatory. A 
successful collaboration between the Complex Biosystems Modeling Laboratory of the 
Massachusetts General Hospital (MGH) in the US, and the In Silico Oncology Group 
(ICCS-NTUA) in the EU, led to the First Transatlantic Workshop on Multiscale 
Cancer Modeling within ICT BIO 2008, co-sponsored by the European Commission 
and the US National Cancer Institute. The above collaboration has also critically 
contributed to the formation of the transatlantic TUMOR project funded by the 
European Commission, linking together EU models (from VPH projects) and US 
cancer models from the Center for the Development of a Virtual Tumor (CViT)
and US front, suggest that by changing 
the manner in which we treat cancer patients, we can maximize the efficiency and 
efficacy of the therapy and, thereby, reduce both the pain and inconvenience to the 
patient and the overall cost to the health service. 
3
The availability of a plethora of EU-US models and their complementarity in 
modeling the various scales of cancer phenomena (from molecular to tissue level), 
allowed the TUMOR partners to develop more complex, and biologically accurate, 
predictive oncology clinical scenarios which are currently being validated. This 
successful collaboration strongly indicates that EU-US synergies can drive much faster 
the developmental milestones needed for clinically translating models and transforming 
them into powerful treatment optimization technology on the clinical setting.
, in 
order to better simulate and predict cancer treatment outcome.  Also, the HAMAM 
project (with US partner the Boca Raton Community Hospital), is joining transatlantic 
forces for more accurate breast cancer diagnosis through integration of biological 
knowledge, novel imaging modalities, and modeling.
Another successful dimension that emanated from TUMOR is that the EU-US 
patient data sharing has been addressed. For the time being, due to the harsh legislation 
2
ContraCancrum has developed models that integrate a broad range of data to define the most appropriate 
treatment, and to predict the patient's likely response to it, in the context of dedicated clinical studies related 
to brain and lung cancer patients at the University of Saarland Hospital. Similarly, the IMPACT project is 
developing a multiscale infrastructure for predicting the Radiofrequency Ablation (RFA) incurred lesion for 
treating cancer in minimally invasive fashion and increasing the survival of patients. The NeoMARK projects 
deals with ICT enabled prediction of cancer reoccurrence.
3
https://www.cvit.org (is administratively located at Massachusetts General Hospital supported by the NIH-
National Cancer Institute.
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in both sides of the Atlantic data need to be stored locally in the EU or US hospital, 
while tools and models will be exchanged and shared instead, in order to run the joint 
workflows and avoid legal and ethical complications. This solution has however 
significant implications for the infrastructure that has to be developed and TUMOR has 
initiated work on analyzing the EU-US legal and ethical regulations and identifying 
possible ways to overcome the many difficulties in harmonizing such regulations. This 
effort will be even more pronounced in a new EC project called p-medicine.
Cardiovascular diseases
Biophysically and anatomically based cell-organ level modelling has recently 
shown to have a great impact in cardiovascular applications.
An example of an EU FP6 funded project which worked in this direction is Health-
e-Child (HeC, www.health-e-child.org). HeC delivered a platform for paediatrics, 
leveraging distributed computing resources federated in a so-called “grid”. Using this 
platform, clinicians are able to run computing intensive tools such as the CaseReasoner, 
a flexible and interactive decision support system, allowing to simultaneously filter 
data and look for similarities across populations of patients, and CardioViz which 
enables the rapid personalisation of the patient’s heart specificities, allowing doctors to 
simulate the effects of heart surgery and overall cardiovascular function over time. 
Worth noting as well, the EU FP7 euHeart project (www.euheart.eu) has been 
developing patient-specific cardiac models combined with anatomical and functional 
pre-operative data to assess the negative or non-response to the implantation of a 
pacemaker as part of Cardiac Resynchronisation Therapy. From the clinical point of 
view, euHeart’s mechanical and electrophysiological cellular models, coupled with 
tissue activation and finite deformation mechanics allow for in-silico tests of different 
device settings (e.g. number and position of leads, chamber delays). 
In the US, in parallel to these EU VPH initiatives, the Johns Hopkins University’s 
Centre for Cardiovascular Bioinformatics and Modelling (www.ccbm.jhu.edu) has 
been developing new methods for the representation, storage, analysis and modelling of 
biological data, and to use such quantitative approaches to better understand healthy
and diseased cardiovascular function. The National Biomedical Computation Resource 
(www.nbcr.net), the National Center for Biomedical Computation at Stanford 
(simbios.stanford.edu), and the Center for Integrative Biomedical Computing 
(http://www.sci.utah.edu/cibc) all have major software development, modelling and 
data dissemination activities in cardiac and vascular physiome research that involve 
numerous international partners including investigators in the UK, Norway, Germany, 
Italy, France, Belgium and the Netherlands, most of who also participate in the VPH 
project. At the time of writing, FDA’s Division of Cardiovascular Devices is leading 
four projects leveraging on simulation-based engineering and medical imaging 
technologies, using computer modelling and image processing techniques to enhance 
the regulatory review process of cardiovascular devices and to shed light on the 
biomechanical environment of the heart.  
Funded through an EU FP7 call specifically designed to internationalise European 
VPH research, Sim-e-Child (SeC) is developing the first grid-enabled trans-Atlantic 
platform for large-scale simulations in paediatric cardiology, offering an online 
collaborative environment for the construction and validation of multi-scale 
personalised simulations of a growing heart and vessels. Thanks to this EU-US 
collaboration, SeC is bringing forward HeC’s promising anatomical and physiological 
models. Three of SeC’s most advanced research areas are:
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! SeC/HeC heart modelling capabilities being validated on an FDA clinical trial 
database (i.e. the Coarctation Of the Aorta Stent Trial [COAST] by the Johns 
Hopkins University hospital, in collaboration with the American College of 
Cardiology, and on newly collected independent MR data at Johns Hopkins 
and Bambino Gesù hospital in Rome, 
! Based on high-quality models of patient-specific geometry and dynamics, 
SeC’s “Cardiac Hemodynamics Computation” tool being developed to 
simulate and analyze the blood hemodynamics within a child’s heart and the 
ascending aorta and aortic arch, 
! SciPort, an online facility for sharing scientific experiments, providing users 
with a multi-site, Web-accessible database of SeC’s paediatric cardiology data, 
information and knowledge for translational research and to support the 
definition, execution and sharing of scientific cardiac modelling and 
simulations. 
Thanks to its enabling trans-Atlantic cooperation, SeC’s goal is to ultimately 
provide clinicians with a model-driven decision support system capable of better 
personalising congenital aortic disease treatment and assessing when to intervene on 
patients. 
8. Lessons learned and needs for future actions
We have learned a number of lessons from these early experiences.  In the 
following they are briefly summarised.
Simple and easy-to-adopt standards: each part of the VPH cyberinfrastructure 
currently stores and communicates data, information, and models with different 
computer formats, many of which are used only in that single service.  To create a 
global VPH cyberinfrastructure we need to establish a set of standardised formats to 
store and communicate data, information, and models.  The problem is only partially in 
the definition of such standards, which for good part already exist, but rather in their 
widespread adoption, which involves simple standards, with adequate support to make 
their adoption easy.  The process must be both bottom-up and top-down, with de facto
standards being progressively experimented in single services and then adopted over 
the whole cyberinfrastructure once they are proved effective, but also with minimal set 
of globally adopted standards defined centrally, and adopted by all services.
Quality Assurance and Validation: as emphasized in the accompanying report on 
Semantic Interoperability, well-structured and consensus-based ontologies, minimal 
information standards and validation protocols are critical pre-requisites for quality 
assurance in complex integrative computer modelling applications, where the model 
assumptions, theoretical formulations, data sources, and numerical methods all affect 
the validity and reliability of the model outcomes and in a manner that is usually 
specific to the context and application of the particular analysis.
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 Outreach and community building as the base for the success of a global 
endeavour: the human factor is of vital importance in fostering any large scale 
collective initiative, and the development of a world-wide VPH cyberinfrastructure is 
not an exception.  Community building, social networking, mechanisms for peer 
recognition and career development, are all necessary elements of such endeavour.
Opportunistic governance, excellence in technology: the development and the 
deployment of the VPH cyberinfrastructure must be driven by an opportunistic 
governance, that foster the development in those directions that are most rewarding for 
our community of users, and that produce the biggest impact in research and clinical 
practice.  It must also consider the development of the commercial and industrial 
dimensions, essential to the long-term sustainability.  On the other hand, this should not 
impair the pursuing of technological excellence.  The VPH cyberinfrastructure is and 
will be one of the most advanced research infrastructures available, from a 
technological point of view. This will drive the excellence also on the application side, 
and will create interesting fall-down onto industrial segments other than healthcare.
Maintenance, transform research prototypes into consolidated resources: the 
majority of the components available are currently at the stage of research prototypes. 
To transform them into consolidated resources that compose the VPH 
cyberinfrastructure will require a considerable amount of work for curation, 
deployment, standardisation and interoperability, etc. And of course, once established 
these services must be operated indefinitely, until such service is found useful and 
valuable by the community.
Outreach: promote and monitor adoption, provide training and support: the 
effective use of a global VPH infrastructure pass also by an aggressive outreach 
activity, which promotes the effective use of the available resources and services, and 
where necessary provides also training and user-support.  In parallel we also need to 
monitor the adoption, understand the “customer satisfaction”, the new needs, etc.
A global VPH cyberinfrastructure policy: the VPH cyberinfrastructure will 
express its full potential only if we design it as a global, worldwide cyberinfrastructure, 
to which every country can access and contribute. This requires a clever governance 
model, which favour de-centralisation of resources and activities, and requires only a 
minimal centrally coordinated effort.  Particularly important here is the integration into 
the VPH cyberinfrastructure of the clinical data, an aspect that poses some problems, 
but also opens up very interesting scenarios.
9. Recommendations 
9.1. Cyberinfrastructure for VPH Research 
This vision of a personalized, predictive, and holistic medicine will become a 
reality only when a comprehensive framework of methods and technologies for 
analyzing organisms as integrated systems has been developed. In the EU, this 
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framework has been sponsored by the European Commission’s Seventh Framework 
Programme and named the Virtual Physiological Human. In the USA and Canada, 
there is no similar coordinated large-scale effort, but similar goals have been articulated
in a variety of publications and venues, notably the Multi-Scale Modeling (MSM) 
consortium of investigators supported by the 12 participating agencies of the 
Interagency Modeling and Analysis Group (IMAG).
The investments that many European and United States funding agencies are 
making in this direction are transforming what was formerly the dream of a handful of 
visionaries into a reality, which is starting to bear fruit. But as the vision of a whole 
new generation of methods and technologies that enable integrative biomedical 
research becomes more concrete, concern is also rising in the research community 
worldwide for the long-term support and viability of a cyberinfrastructure consisting of 
new tools, services, and data collections that will be needed for the widespread 
adoption of integrative approaches within the existing research infrastructure. 
While the mechanisms exist to maintain the infrastructures already available for 
biomedical research worldwide, the concern is that the revolutionary nature of the VPH 
cyberinfrastructure will require special policies to its long-term sustainability. 
In particular three aspects appear of fundamental relevance: maintenance, service,
and outreach.
! Maintenance: we need to transform the research prototypes developed in the 
various research projects into consolidated resources, through a process of re-
engineering, consolidation, standardization, and maintenance. Such activities 
cannot be supported with the funding mechanisms available from most 
funding agencies, though there are isolated programs supported by NIH and 
other agencies for maintaining specific software and data resources. And 
recently the United States NSF has recognized this problem through its 
establishment of the Scientific Software Innovation Institutes [27]. By their 
nature, in order to be effective there should also be strong international 
collaboration in these projects; and similar initiatives should be created also in 
Europe.
! Service: we need to deploy these consolidated technologies into services that 
are operated and curated in ways that ensure their persistence, reliability, 
security, etc.  This is an essential requirement if we want the vision of 
integrative biomedical research, with all its advantages, to percolate deeply 
into the worldwide practice of research, and into its most relevant clinical 
applications.
! Outreach: motivated organizations must be established and supported not 
only to operate these services, but also to promote an outreach campaign that: 
a) ensures the widest possible adoption and utilization of the computational 
model based research technologies; b) provides training and re-training to 
researchers and medical professionals in these technologies and 
methodologies, to ensure their most effective and appropriate usage; and c) 
monitors the development and the adoption of information and computational 
modelling technologies in research and healthcare, providing decision-makers 
with factual and up-to-date evidence on which to base policy decisions and to 
communicate the impact of investments made in this domain.
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9.2. The role of the VPH Cyberinfrastructure in biomedical research
The contribution that such a cyberinfrastructure can make for research is already 
quite clear.  Biomedical research in most of its branches and articulations is 
progressing towards comprehensive digitization of experimental observations and the 
associated information; this will make it possible to share with our peers not only the 
conclusions we draw from such observations, but also the raw data themselves.  By 
speeding up the circulation of data, we can expect a better peer-reviewing process, and 
the reuse of experimental data in new contexts and applications, reducing the costs of 
research.  This process is already under way.
But the VPH vision goes much beyond this.  With predictive models it is possible 
to capture in a digital and reusable form the knowledge we produce as scientists. A 
global cyberinfrastructure where such models can be accessed, used to elaborate other 
data, and combined to form a holistic understanding of complex processes could be a 
real breakthrough for biomedical research.  
Once available through the VPH cyberinfrastructure, reusable models can be 
combined to describe processes that involve more than one function of the body, at 
different scales from the whole body down to the atoms.  Owing to the specialization of 
biomedical research, it is a rare expert in cardiovascular biology that is also well versed 
in neuroscience or orthopaedics for example, despite the critical interactions between 
these systems.  So it should not be a surprise to find out that the vascularisation of the 
bones tissue, in spite of being a vital process both in physiological and pathological 
conditions, has been poorly investigated to date. 
But it is probably the last point that is the most exciting of all. There is 
increasingly strong evidence that biological processes are characterized by 
unexpectedly complex upward and downward causations that link processes and events 
that occur at radically different space-times scales, across sub-systems, and involving 
different bodies of knowledge. In some cases, it is now clear that what we observe is 
the emergence of the systemic interaction of a complex system; this means that 
studying any part of the process will never fully explain the observations we make. 
This realization is also driving the “omic” approach to personalized medicine. Only by 
studying the system, made of all its parts, will we be able to obtain good explanations 
of what we observe.  
But how can this vision of an integrative biomedical research be done in practice? 
The VPH cyberinfrastructure will help make it possible to curate accurate models of 
each part of the system, store it in a digital artefact, share it electronically, so as to 
allow the combination of these parts into integrative models capable of explaining 
complex systemic interactions, which might be otherwise defy intuitive explanation.
9.3. The role of the VPH Cyberinfrastructure in clinical practice
The VPH cyberinfrastructure will impact clinical practice in two ways. The first is 
clinical decision support, where Internet-based services based on fully validated 
integrative models will be used by properly trained clinical users to integrate the data 
and information available on the patient with the existing knowledge relevant to the 
clinical problem.  Such knowledge is captured in the integrative model, so as to provide 
support and assistance during prevention, diagnosis, prognosis, treatment planning and 
execution, monitoring, and rehabilitation. Already today, VPH models are being used 
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to help identify responders to cardiac resynchronization therapy and make it a more 
cost-effective repeatable and reliable treatment for patients with dyssynchronous heart 
failure. Similar results are being reported in pre-clinical or early clinical trials in other 
domains such as treatment planning in acute myocardial infarction, diagnosis of the 
risk of fracture in osteoporosis, model-guided ablation of liver tumours, etc.
A second way through which the VPH cyberinfrastructure promises to impact 
clinical practice is via the biomedical therapeutics industries. The large-scale 
availability of data and models about human physiology and pathology will make it 
easier to conduct preliminary investigations on the safety and the efficacy of new 
medical devices with computers, in order to reduce risks and costs associated with 
clinical trials. VPH models will also make it easier to test whether modifications to 
existing therapies might produce unintended consequences, thus improving patient’s 
safety. In pharmacology, molecular and cellular modelling are transforming drug 
discovery. For example, one of the EU VPH projects, PreDICT, is developing 
computer simulations to assess the risk of cardio-toxicity for new compounds. As the 
VPH cyberinfrastructure develops, it will become easier and more effective for 
regulatory authorities to verify that the pre-requisite conditions exist to start new 
clinical trials, through the availability of standard simulation benchmarks that all 
products of a given category must pass.  Scenarios are also emerging where medical 
technologies for diagnosis, planning, or treatment are augmented with VPH models that 
can transform patient data into predictions of the natural history of disease, treatment 
outcomes, and prognosis. There is now also considerable penetration of population-
based modelling in developing clinical guidelines, healthcare policies and designing 
clinical trials [28].
9.4. Impact of the VPH cyberinfrastructure on eHealth at large
Interoperability, standardisation, and certification
The VPH cyberinfrastructure will have to enable the integration of disparate 
biomedical data, information, and knowledge, including those contained in current 
hospital information systems. This is why the VPH initiative aims to follow closely the 
efforts at standardization and interoperability of the information contained in electronic 
health records (EHR). Furthermore, given the VPH initiative’s definition of health to 
encompass environmental and lifestyle factors, interoperability efforts must be 
extended to also include data from personal health systems (PHS), personal health 
records (PHR), and, eventually, from databases mapping environmental/ecological 
variables with health variables. 
Semantic interoperability requires the use of standards that will enable the clinical 
content of the EHR to be interpreted consistently across different EHR regimes. 
Accurate and complete clinical documentation and interoperability between systems 
require widespread and dependable access to published and maintained collections of 
coherent and quality-assured semantic resources, including for example models such as 
archetypes and templates that provide clinical context, mapped to interoperability 
standards for EHR and PHR and biomedical data, linked to well specified terminology 
value sets, derived from high quality ontologies. 
The VPH is already now discussing the technical and semantic interoperability of 
types of data and information that may soon become part of mainstream healthcare, and 
thus part of EHRs; the work VPH delivers should provide a useful starting point for 
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any extension effort by the electronic health record standardization bodies and 
organisations, and other eHealth stakeholders. 
Promotion of continuous innovation through impact assessment
The EU-US MoU on Health Related Information and Communication 
Technologies calls for a framework that articulates how health-related ICT support 
does and can potentially improve health, i.e. the assessment of the economic benefits of 
eHealth. In the same way, the VPH cyberinfrastructure will employ means and 
expertise to guide the promotion of continuous innovation through impact assessment 
and the measuring of its adoption, usage, and benefits. To monitor and guide the 
development, implementation, and success of the VPH cyberinfrastructure, it is 
necessary to measure the diffusion and usage of its services and applications across 
health service actors and across the research communities. At the level of any member 
state or regional health system, this necessitates a clear understanding of the role of 
measurements, indicators and benchmarking in policy and their appraisal for policy 
making – for research, innovation, health, and social care policy planning. 
Measuring and assessing benefits for policy making
In many contexts, health technology assessment (HTA) has become the preferred 
approach for policymakers to base decisions on health technology investments and 
reimbursement policies on factual evidence, gained as independently as possible from 
the many biases that tend to revolve around the introduction of a new health technology.
On the problem of measuring the adoption, usage, and benefits of eHealth 
technologies, the contribution of the VPH initiative will be primarily related to the 
development of new HTA approaches, with the VPH cyberinfrastructure contributing 
to benchmarking performances. Both do not have to begin only after the technology 
will have been fully deployed, but before, when the technology is in the research and 
development phase. This will help steering public and private research investments 
towards those approaches that show the highest potential for efficacy and other benefits. 
This implies new challenges for benefits assessment and requires new approaches and 
methods to be defined and identified. There is a need for a more dynamic approach to 
impact assessment of medical technologies, and in particular of VPH-based technology 
and cyberinfrastructure.
The assessment of benefits arises directly from the effective use of ICT 
(“meaningful use”). Such socio-economic evaluations of the impact VPH technologies 
and the cyberinfrastructure will have on research, clinical, and industrial domains can 
offer significant advice and support to health policy decision-makers. A major reason 
for the relatively slow progress in eHealth deployment is the lack of awareness of 
robust empirical evidence on benefits, which in turn could feed into sustainable 
business cases, driving economic activity and boosting the diffusion of innovation. 
VPH fully understands that there is a need to disseminate existing best practices and 
the associated benefits as well as to examine existing methodologies of economic 
assessment. There is a need to propose common approaches to proving benefits of 
interoperable solutions and infrastructures using coherent and quantitative (scientific) 
methods.
Benchmarking adoption and usage for the monitoring of policy impact
For the VPH cyberinfrastructure to deliver the expected benefits, from a regulatory 
aspect, two policies are required: policies to foster actual deployment (including 
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investments, improvement of interoperability, reducing legal and other barriers) and 
policies to monitor policy impact itself.  For this monitoring, measures of deployment, 
diffusion, usage and the effectiveness of current and future take-up are needed, 
typically realised through benchmarking. 
The evaluation of the VPH cyberinfrastructure developments and outputs through 
benchmarking can take place along dimensions like:
! accessibility and usability for simulation and modelling efforts; 
! accessibility and ability to interface with other infrastructures (resources, tools 
and methods); 
! potential interfaces to and integration with EHR and PHR systems; 
! perceived and experienced benefits by type of user;
! facilitation of virtual collaborations between members with different expertise;
! uptake and acceleration of model development and integration.
In more concrete terms, the particular success of the VPH cyberinfrastructure can 
be directly benchmarked by monitoring these levels of supply and demand:
! The number of sites, portals, and services that share as digital artefacts data, 
information, and knowledge captured into models, concurring the global VPH 
cyberinfrastructure, as well the number of artefacts that the cyberinfrastructure 
deploys;
! The number of users of the artefacts the VPH cyberinfrastructure distributes, 
and their number of accesses, clustered by research, clinical and industrial 
applications.
Indirectly, the VPH Cyberinfrastructure can be benchmarked by measuring the 
impact the VPH initiative will have on research, clinical, and industrial domains 
through the following indicators:
! The number of international peer-reviewed publications targeting biomedical 
researches where VPH-related technologies were used to unravel relevant 
research questions. This indicator quantifies the impact of the VPH vision 
onto biomedical research at large.
! The number and size of clinical trials that aim to evaluate the clinical accuracy, 
clinical efficacy, and clinical impact of VPH-related technologies and services. 
This indicator quantifies the rate of translation of VPH-derived technologies to 
clinical practice.
! The number and size of VPH-based medical technology products and services 
that enter the market. This indicator quantifies the level of adoption of VPH-
based technologies in clinical practice.
9.5. The role of the VPH Cyberinfrastructure in Pharmaceutical Discovery and 
Medical Device Development
There is near-term potential for integrative physiological modeling to accelerate 
device and drug development and facilitate regulatory approvals. In the US and Europe, 
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companies such as Entelos are already proving integrative modeling tools and services 
to these industries. The US FDA has shown interest in the role of computational 
modeling for improving the development and regulatory assessment of implanted 
devices and organizes an annual meeting on the topic of modeling cardiovascular 
devices and their interaction with the circulatory system in vivo. Models have 
significant potential to support filings for regulatory approvals by permitting a larger 
range of conditions to be investigated than can be studied experimentally and by 
facilitating the integration of reconciliation of diverse data from pre-clinical bench and 
animal testing and clinical trials. The challenge for regulatory agencies will be to find 
ways to encourage the adoption of integrative modeling by the device and 
pharmaceutical industries without compromising competitiveness with mandates that 
single corporations will not have the in-house infrastructure to meet. The proposed 
VPH Cyberinfrastructure could help regulators to address this challenge.
In drug development, the pharmaceutical industry has long recognized the role of 
pharmacokinetic (PK) modeling (“simulating what the body does to the drug”) and 
pharmacodynamics (PD) modeling (“simulating what the drug does to the body”). 
Consider, for example, the kinetic distribution of a drug or toxic compound throughout 
the body. Understanding and predicting drug distribution is a critical part of the 
decision making process in therapeutics. The pharmacokinetics observed in a rat, for 
example, will not exactly mimic that observed in a human. Nor will the kinetics 
observed on one human necessarily parallel that in another. However, if the underlying 
processes governing the pharmacokinetics in a mammalian system can be captured in a 
physiologically-based model, then that model can be readily scaled accounting for 
differences in organ and tissue masses, relative proportions of fat, and relative blood 
flows, to make predictions for one specific species (or individual) based on 
measurements in another.
Pharmacokinetics represents one of many potential applications using 
computational simulation as a tool for translation. A common infrastructure (of 
ontologies, data standards, model standards) is needed to facilitate this translational 
potential. Such an infrastructure will open the door to: sharing data and applications 
between clinical and basic research domains, to multiple parallel approaches to 
integrating and probing patient data, and to making connections between basic research 
and clinical applications.
9.6. The role of the VPH Cyberinfrastructure in environmental regulation
There is a pressing need for reliable biological models to assist in the regulation of 
industrial chemicals. Both the EU and the US have large ongoing efforts in developing 
computational models to assist non-medical regulatory decision making processes. As 
these aspects do not directly relate to a specific disease, or a specific medical treatment, 
the community of practice behind environmental research and regulatory affairs is 
largely distinct from that involved with eHealth.  However, both contexts require a 
VPH Cyberinfrastructure; it would be unfortunate if two incompatible infrastructures 
were developed for these two related domains, missing the considerable synergies that 
the application of VPH technologies could provide in common areas such as research 
or regulatory affairs.
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9.7. The role of the VPH Cyberinfrastructure in personal health services
On the horizon of health policies is appearing, in relation to multiple socio-
economic challenges such as prevention, chronic diseases, or active and health ageing, 
a completely new scenario where the citizen/patient becomes a prime actor in the 
collection and management of information about his/her health.  This involves the 
collection of personal health data (personal health systems) and the management of 
health information (personal health record).  In this context the global VPH 
Cyberinfrastructure could provide two essential services: 
! Integration and dynamic exchange of key information between the personal 
health record and the clinical health information systems, both electronic 
health record and clinical research databases;
! Provision of Personal Health Forecasters [29], services that constantly 
process personal health data to predict health risks, the appearance of specific 
conditions, or simply advise the patient on specific lifestyle aspects.
9.8. Benchmarking
The success of the VPH cyberinfrastructure can be directly benchmarked by 
monitoring the levels of offer and demand:
! The number of sites, portals, and services that share as digital artefacts data, 
information, and knowledge captured into models, concurring the global VPH 
cyberinfrastructure, as well the number of artefacts that the cyberinfrastructure 
deploys;
! The number of users of the artefacts the VPH cyberinfrastructure distributes, 
and their number of accesses, clustered by research, clinical and industrial 
applications.
Indirectly, the VPH Cyberinfrastructure can be benchmarked by measuring the 
impact the VPH initiative will have on research, clinical, and industrial domains 
through the following indicators:
! The number of international peer-reviewed publications targeting biomedical 
researches where VPH-related technologies were used to unravel relevant 
research questions. This indicator quantifies the impact of the VPH vision 
onto biomedical research at large.
! The number and size of clinical trials that aim to evaluate the clinical accuracy, 
clinical efficacy, and clinical impact of VPH-related technologies and services. 
This indicator quantifies the rate of translation of VPH-derived technologies to 
clinical practice.
! The number and size of VPH-based medical technology products and services 
that enter the market. This indicator quantifies the level of adoption of VPH-
based technologies in clinical practice.
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9.9. Governance model
The distributed, international, loosely coupled nature of the VPH 
Cyberinfrastructure recalls a famous sibling: the Internet. The network of the networks 
has a governance model that has been revised and adjusted over the years, while 
enabling the Internet to grow rapidly and flourish beyond all expectation. With this 
inspiration, we propose the following governance steps:
1) Establish a permanent Observatory on eHealth:
A first step toward the creation of a worldwide VPH Cyberinfrastructure could be 
the transformation of the ARGOS Transatlantic Observatory for Meeting Global Health 
Policy Challenges through ICT-Enabled Solutions into a permanent body.  For what 
matters the VPH part of ARGOS this is already happening. The recently established 
VPH Institute has already announced that within 2011 will be established a permanent 
international observatory on the VPH initiative, hosted by the VPH Institute, and 
formed by representatives of relevant worldwide scientific societies, of public agencies 
funding VPH-related research, and of clinical, industrial, and societal stakeholders.  
2) Establish a Multistakeholder Advisory Group (VPH/MAG) to:
! Constantly review the goals of the Cyberinfrastructure;
! Promote the development of standards for interoperability and integratibility;
! Maintain a worldwide research roadmap;
! Develop regulatory guidelines and processes in cooperation with regulatory 
bodies.
Such an advisory group could be established at the very beginning of the initiative. 
Its structure would include a master board where all stakeholders are properly 
represented, and a series of work groups, much like the Internet Engineering Task 
Force, that would produce technical recommendations and specifications related to the 
operations of the VPH Cyberinfrastructure. 
3) Establish a globally distributed cyberinfrastructure:
! Whose backbone is operated by a private not-for-profit organization;
! Whose leafs are voluntarily interconnected cyberinfrastructures operated at 
regional, state, and/or federal levels.
Essentially, we propose to minimize the role of the centralized authority, 
delegating this role to a private non-profit organization, designed on the model of the 
Internet Corporation for Assigned Names and Numbers  (ICANN), that would be 
responsible to ensure through training, certification, and auditing services that all 
peripheral nodes of the VPH Cyberinfrastructure correctly comply with the agreed 
interoperability standards, and provide the global integration level services such as 
management of the VPH cyberinfrastructure main portal, and global services such as 
ID management, directory, namespaces resolution, etc. Most of the work would be 
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done by the peripheral nodes, which would be operated, governed and funded 
autonomously by the various local authorities. 
4) Commit the financial support
We expect that government agencies may initially need to provide financial 
support for the Cyberinfrastructure, though much of this support might be provided in 
kind by allocating existing staff and infrastructures, where reorganization plans de-
allocate some of them from other mission (i.e. the re-organization of HPC centers that 
is happening in many countries in relation to the changes in the demand of high-
performance computing). However, we also feel that because of the research 
efficiencies and high translational potential for this research, the Cyberinfrastructure 
should eventually derive most of its financing from the pharmaceutical, medical device 
and healthcare industries that benefit from its deployment.
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